East Bay cancer drug developer targets $100 million IPO
February 16, 2018 at 17:48 PM EST
Backed by GV, The Column Group, Celgene and others, this cancer drug developer already has more than 80 people on staff.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|